Neurosignals 2008;16:99–105
(DOI:10.1159/000109764)

Mutations in LRRK2 as a Cause of Parkinson’s Disease

Giasson B.I.a · Van Deerlin V.M.b
Departments of aPharmacology and bPathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pa., USA
email Corresponding Author


 goto top of outline Key Words

  • α-Synuclein
  • Kinase
  • LRRK2
  • PARK8
  • Parkinson’s disease

 goto top of outline Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of late-onset Parkinson’s disease (PD). Clinical and pathological studies have demonstrated that in the majority of cases LRRK2 mutations lead to PD with classical clinical and pathological features. However, in some patients the pathological features can be distinct and/or more extensive than typically seen in PD. Collectively, these findings provide important clues into the mechanisms by which LRRK2 mutations can lead to demise of dopaminergic neurons. The understanding of LRRK2 protein function and its gene regulation and the consequences of mutations are still at their infancy, but scientific findings are progressing at a rapid pace. Although more detailed information on LRRK2 is still needed in the quest for therapeutic intervention that could halt or slow the progression of disease, here we summarize the current information on the biological and pathological properties of LRRK2.

Copyright © 2008 S. Karger AG, Basel


 goto top of outline References
  1. Simuni T, Hurtig HI: Parkinson’s disease: the clinical picture; in Clark CM, Trojanowski JQ (eds): Neurodegenerative Dementias. New York, McGraw-Hill, 2000, pp 193–203.
  2. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39.
  3. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen DA, Pakkenberg H: The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30–33.
  4. Damier P, Hirsch EC, Agid Y, Graybiel AM: The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122:1437–1448.
  5. Forno LS: Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996;55:259–272.
  6. Forman MS, Lee VM, Trojanowski JQ: Nosology of Parkinson’s disease: looking for the way out of a quagmire. Neuron 2005;47:479–482.
  7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
  8. Goedert M: α-Synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492–501.
  9. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601–607.
  10. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der BM, de Munain AL, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB: Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004;44:595–600.
  11. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM: Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102:16842–16847.
  12. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M: The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006;15:223–232.
  13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329–341.
  14. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM: Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006;59:315–322.
  15. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL: Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006;60:557–569.
  16. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z: Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants. J Neurochem 2007;103:238–247.
  17. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC: Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain. Brain Res 2007;1155:208–219.
  18. Higashi S, Moore DJ, Colebrooke RE, Biskup S, Dawson VL, Arai H, Dawson TM, Emson PC: Expression and localization of Parkinson’s disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem 2007;100:368–381.
  19. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M: Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006;139:791–794.
  20. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ: A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007;147:1047–1058.
  21. Taymans JM, Van den HC, Baekelandt V: Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 2006;98:951–961.
  22. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L: LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 2006;59:714–719.
  23. Simon-Sanchez J, Herranz-Perez V, Olucha-Bordonau F, Perez-Tur J: LRRK2 is expressed in areas affected by Parkinson’s disease in the adult mouse brain. Eur J Neurosci 2006;23:659–666.
  24. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA: Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231–1233.
  25. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM: Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16:223–232.
  26. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR: LRRK2 phosphorylates moesin at threonine-558:characterization of how Parkinson’s disease mutants affect kinase activity. Biochem J 2007;405:307–317.
  27. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR: The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007;357:668–671.
  28. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T: GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson’s disease. Biochemistry 2007;46:1380–1388.
  29. Macleod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A: The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006;52:587–593.
  30. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA: LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci 2006;29:286–293.
  31. Taylor JP, Mata IF, Farrer MJ: LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 2006;12:76–82.
  32. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al Khairallah T, George-Hyslop P, Singleton A, Rogaeva E: LRRK2 gene in Parkinson disease. Neurology 2005;65:696–700.
  33. Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J: Genetic and clinical identification of Parkinson’s disease patients with LRRK2 G2019S mutation. Ann Neurol 2005;57:933–934.
  34. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V: A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 2005;365:412–415.
  35. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M: Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672–680.
  36. Hernandez D, Paisan RC, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, Dickson D, Wavrant DF, Hardy J, Singleton A: The dardarin G2019S mutation is a common cause of Parkinson’s disease but not other neurodegenerative diseases. Neurosci Lett 2005.
  37. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T: Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 2005;365:410–412.
  38. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW: A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 2005;365:415–416.
  39. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, Durr A, Brice A: G2019S LRRK2 mutation in French and North African families with Parkinson’s disease. Ann Neurol 2005;58:784–787.
  40. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A: LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 2006;354:422–423.
  41. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB: LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2006;354:424–425.
  42. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, Weng YH, Rohe CF, Breedveld GJ, Hattori N, Gasser T, Oostra BA, Bonifati V: The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord 2005;11:521–522.
  43. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ: The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett 2005;384:327–329.
  44. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, Pezzoli G: Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007;68:1141–1143.
  45. Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM: LRRK2 mutations in Parkinson disease. Neurology 2005;65:738–740.
  46. Hernandez DG, Paisan-Ruiz C, McInerney-Leo A, Jain S, Meyer-Lindenberg A, Evans EW, Berman KF, Johnson J, Auburger G, Schaffer AA, Lopez GJ, Nussbaum RL, Singleton AB: Clinical and positron emission tomography of Parkinson’s disease caused by LRRK2. Ann Neurol 2005;57:453–456.
  47. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M: Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol 2005;57:762–765.
  48. Giordana MT, D’Agostino C, Albani G, Mauro A, Di Fonzo A, Antonini A, Bonifati V: Neuropathology of Parkinson’s disease associated with the LRRK2 Ile1371Val mutation. Mov Disord 2007;22:275–278.
  49. Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO, Farrer MJ: LRRK2 mutations are not common in Alzheimer’s disease. Mech Ageing Dev 2005;126:1201–1205.
  50. Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD, Payami H: Analysis of the LRRK2 G2019S mutation in Alzheimer disease. Arch Neurol 2006;63:156–157.
  51. Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW: G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 2007;22:546–549.
  52. Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ: Analysis of 14 LRRK2 mutations in Parkinson’s plus syndromes and late-onset Parkinson’s disease. Mov Disord 2006;21:997–1001.
  53. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW: Lrrk2 and Lewy body disease. Ann Neurol 2006;59:388–393.
  54. Ross OA, Whittle AJ, Cobb SA, Hulihan MM, Lincoln SJ, Toft M, Farrer MJ, Dickson DW: Lrrk2 R1441 substitution and progressive supranuclear palsy. Neuropathol Appl Neurobiol 2006;32:23–25.
  55. Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, Mash DC: Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 2006;63:1242–1246.
  56. Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E: G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 2007;78:626–628.
  57. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ: Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006;67:1506–1508.
  58. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F: An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005;57:918–921.
  59. Hasegawa K, Kowa H: Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur Neurol 1997;38(suppl 1):39–43.
  60. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619–1622.
  61. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V: Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet 2006;14:322–331.
  62. Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, Volkmann J, Pramstaller PP, Kostic V, Vieregge P, Klein C: Recurrent LRRK2 (Park8) mutations in early-onset Parkinson’s disease. Mov Disord 2006;21:1506–1510.
  63. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW: Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128:2786–2796.
  64. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA: Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005;102:18676–18681.
  65. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, Gouider-Khouja N, Kefi M, Zouari M, Ben Sassi S, Ben Yahmed S, Euch-Fayeche G, Middleton L, Burn DJ, Watts RL, Hentati F: Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson’s disease families. Mov Disord 2007;22:55–61.

 goto top of outline Author Contacts

Dr. Benoit I. Giasson
Department of Pharmacology, University of Pennsylvania School of Medicine
3620 Hamilton Walk, 125 John Morgan Building
Philadelphia, PA 19104-6084 (USA)
Tel. +1 215 573 6012, Fax +1 215 573 2236, E-Mail giassonb@mail.med.upenn.edu


 goto top of outline Article Information

Published online: December 5, 2007
Number of Print Pages : 7
Number of Figures : 2, Number of Tables : 0, Number of References : 65


 goto top of outline Publication Details

Neurosignals

Vol. 16, No. 1, Year 2008 (Cover Date: December 2007)

Journal Editor: Ip, N.Y. (Hong Kong)
ISSN: 1424–862X (print), 1424–8638 (Online)

For additional information: http://www.karger.com/NSG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.